FDA, EMA Valsartan Update, New Data on Cancer Risk FDA, EMA Valsartan Update, New Data on Cancer Risk

The FDA and EMA report a possible second carcinogen in previously withdrawn vasartan products, while a new analysis finds no increased cancer risk in those who previously took contaminated valsartan.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news

Related Links:

Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma, Published online: 23 January 2019; doi:10.1038/s41417-019-0080-3Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS:: Dose increase for Zirconia was noted to be maximum while PEEK implant dose increase was minimum among the whole dental implant materials studied. This study revealed that the Eclipse TPS PBC algorithm could not accurately estimate the backscatter radiation from dental implant materials. PMID: 30663343 [PubMed - as supplied by publisher]
Source: Dentomaxillofacial Radiology - Category: Radiology Tags: Dentomaxillofac Radiol Source Type: research
Date: Friday, 02 22, 2019; Speaker: F. Stephen Hodi, M.D., Director of the Melanoma Center and the Center for Immuno-Oncology, Dana-Farber Cancer Institute; Building: Building 10 (Clinical Center); Lipsett Amphitheater; CME Credit; Videocast Event
Source: NIH Calendar of Events - Category: American Health Source Type: events
In this study, the osteoconductivity of Fe3O4-rGO nanocomposites of various compositions was evaluated in vitro in terms of their apatite-forming ability in simulated body fluid (SBF). Furthermore, the heat generation of the nanocomposites was measured under an alternating magnetic field. The apatite-forming ability in SBF improved as the Fe3O4 content in the nanocomposite was increased. As the Fe3O4 content was increased, the nanocomposite not only rapidly raised the surrounding temperature to approximately 100 °C, but the specific absorption rate also increased. We assumed that the ionic interaction between the Fe3...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
(CNN) — A simple blood test could predict if a patient will develop Alzheimer’s disease up to 16 years before symptoms begin, a new study finds. By measuring changes in the levels of a protein in the blood, called neurofilament light chain (NfL), researchers believe any rise in levels of the protein could be an early sign of the disease, according to the study published Monday in the journal Nature Medicine. NfL is a “marker in the blood which gives an indication of nerve cell loss in the brain,” explained lead researcher Mathias Jucker, professor of cell biology of neurological diseases at the Germ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News Alzheimer's Disease CNN Local TV Source Type: news
Publication date: Available online 21 January 2019Source: Journal of Clinical NeuroscienceAuthor(s): Satish Krishnamurthy, Jie Li, Alexa Bodman, Chaozai Zhang, Yilei Yang, Jing AnAbstractAdvances in therapies for breast cancer with cerebral metastases has been slow, despite this being a common diagnosis, due to limited drug delivery by the blood brain barrier. Improvements in drug delivery for brain metastasis to target the metastases and bypass the blood brain barrier are necessary. In our study, we delivered an inhibitor of chemokine receptor 4 by convection enhanced delivery in a hyperosmotic solution to prevent brain m...
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
The U.S. Food and Drug Administration said on Friday it had approved a biosimilar to Roche Holding AG's blockbuster breast cancer treatment, Herceptin.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
In conclusion, it is suggested that c2orf68 is a potential carcinogenesis factor in rectal cancer. Furthermore, c2orf68 may have a synergistic effect with HuR in the onset and development of CRC. PMID: 30664176 [PubMed - as supplied by publisher]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Authors: Fontes-Sousa M, Amorim M, Salta S, Palma De Sousa S, Henrique R, Jerónimo C Abstract Notwithstanding the marked progress in breast cancer (BC) management, it still constitutes the most common malignancy in women and a major cause of morbidity and mortality, thus remaining a major health issue worldwide. Most BC cases are hormone receptor (HR) positive (luminal A or B molecular subtypes) and endocrine treatment (ET) is an important therapeutic modality at all disease stages. Nevertheless, despite substantial improvements in BC patient outcome, effectiveness of ET is limited, as up to 40% of patients ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
miR663a‑TTC22V1 axis inhibits colon cancer metastasis. Oncol Rep. 2019 Jan 16;: Authors: Tian W, Du Y, Ma Y, Zhang B, Gu L, Zhou J, Deng D Abstract An increasing number of studies have demonstrated that microRNAs (miRs) may act as oncogenes or anti‑oncogenes in various types of cancer, including colon cancer (CC). However, the clinical and biological significance of miR663a in the prognosis of CC and its underlying molecular mechanisms remain unknown. Using the reverse transcription‑quantitative polymerase chain reaction on CC and surgical margin tissue samples from 172 patients with CC, it was ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Diovan | Heart